Dizlin Pharmaceuticals AB – Trademark Portfolio
Entity Type: 64
Dizlin Pharmaceuticals AB holds 7 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 7 filings in this category. The portfolio also extends into Class 10 (Medical Apparatus) across 3 Nice Classification classes. Currently, 4 trademarks are registered and 2 are pending. Notable registered marks include SUBC, DIZLIN, INTRAV, and INFUDOPA. The owner is based in Göteborg.
Sahlgrenska Science Park
Medicinaregatan 8A
Göteborg 413 90 , SE
Showing of trademarks Trademarks
Trademark Classifications
Dizlin Pharmaceuticals AB's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Frequently Asked Questions
How many trademarks does Dizlin Pharmaceuticals AB have?
Dizlin Pharmaceuticals AB has 7 U.S. trademarks filed with the USPTO. Of these, 4 registered, 2 pending.
What trademark classes does Dizlin Pharmaceuticals AB file in?
Dizlin Pharmaceuticals AB files trademarks across 3 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 44 (Medical Services). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Dizlin Pharmaceuticals AB's most well-known trademarks?
Dizlin Pharmaceuticals AB's registered trademark portfolio includes well-known marks such as SUBC, DIZLIN, INTRAV, and INFUDOPA. These are among 4 currently registered trademarks in the portfolio.
What is Dizlin Pharmaceuticals AB's trademark registration success rate?
Dizlin Pharmaceuticals AB has a 100% trademark registration rate, with 4 out of 4 resolved applications resulting in successful registration. Currently, 2 applications are pending review.